High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Autor: | Ilkka Vihriälä, Jari Punkkinen, Tero Ylisaukko-oja, Taina Sipponen, Eija Hirsi, Christian Nielsen, Jyrki Tillonen, Markku Pajala, Jouni Silvennoinen, Ville Liukkonen, Mikko Kellokumpu, Jari Jokelainen, Henna Rautiainen, Veikko Moilanen, Hans Henricson, Hannu Sulonen, Mirva Esterinen, Timo Blomster, Kari Toljamo, Klaus Tamminen, Pauliina Molander, Airi Jussila, Jaakko Aaltonen, Juha Kuisma, Petri Mäkelä, Kalle Hakala, Margus Lääne, Kimmo Salminen, Sauli Herrala, Ulla-Maija Suhonen, Mika Puhto, Markku Peräaho, Heikki Nuutinen |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty Antibodies Monoclonal Humanized Severity of Illness Index Inflammatory bowel disease Vedolizumab Young Adult 03 medical and health sciences 0302 clinical medicine Crohn Disease Gastrointestinal Agents Internal medicine Humans Medicine Finland Retrospective Studies Wound Healing Crohn's disease business.industry Remission Induction Gastroenterology Endoscopy Retrospective cohort study Middle Aged ta3121 medicine.disease Ulcerative colitis digestive system diseases 3. Good health Biological Therapy Clinical trial Tolerability 030220 oncology & carcinogenesis Colitis Ulcerative Female 030211 gastroenterology & hepatology business Cohort study medicine.drug |
Zdroj: | Scandinavian Journal of Gastroenterology. 53:158-167 |
ISSN: | 1502-7708 0036-5521 |
Popis: | Objectives: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, therefore, it is important to demonstrate effectiveness in real-life clinical practice. We set out to assess real-world treatment outcomes of vedolizumab in a nationwide cohort of treatment refractory Finnish Crohn’s disease (CD) and ulcerative colitis (UC) patients. Methods: This was a nationwide, retrospective, non-interventional, multi-centre chart review study. All adult patients from 27 Finnish gastroenterology centers with a diagnosis of UC or CD who had at least one vedolizumab infusion since the availability of the product in Finland, were included in the study. Data were collected retrospectively from medical charts at baseline, week 14, and month 6. The primary outcome measure was treatment persistence 24 weeks post-vedolizumab initiation. Results: A total of 247 patients were included (108 CD, 139 UC). A total of 75.0% (n = 81) of all CD patients and 66.2% (n = 92) of all UC patients, were persistent on vedolizumab therapy for 6 months post treatment initiation. At month 6, 41.8% (28/67) of the treatment persistent CD patients and 73.3% (63/86) of the treatment persistent UC patients achieved clinical remission. Significant improvement in endoscopic scores were observed among treatment persistent patients (CD, n = 17, ΔSES-CD=−5.5, p = .008; UC, n = 26, ΔMayo endoscopic score =−0.5, p = .003) at month 6. Conclusions: Vedolizumab provides an effective and well-tolerated treatment option in real-world clinical practice even among treatment refractory IBD patients. |
Databáze: | OpenAIRE |
Externí odkaz: |